Sep 30, 2020
MediSieve Participates in Cycle4Sepsis
Throughout September 2020 MediSieve took part in UK Sepsis Trust's initiative Cycle4Sepsis.
The UK Sepsis Trust was founded in 2012 by NHS consultant, Dr Ron Daniels BEM. Renowned for his systems and translational expertise, Ron had spent the previous 7 years developing and disseminating the Sepsis 6 pathway across the NHS and globally. The Trust seeks to save lives and to improve outcomes for survivors, by instigating political change, educating healthcare professionals, raising public awareness and providing support for those affected by this devastating condition.
As fundraising is at the heart of the fight against sepsis, throughout September 2020 MediSieve took part in UK Sepsis Trust's initiative Cycle4Sepsis. The campaign aims to raise vital funds and awareness for the disease. The team covered a total of 640 miles, greatly outperforming the original plan of 40 miles. This is not the first time the company has collaborated and fundraised for The UK Sepsis Trust. Prior to the pandemic the company has organised a bake sale, donating all profits to the Trust.
Thanks to kind donors and sponsors MediSieve raised 1113 £ for the cause. The team is thankful for the support and continues to fight sepsis through its Magnetic Blood Filtration technology! MediSieve is looking forward to any future events and initiative to fundraise for the organisation.
More information about the event:
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
INVESTOR AND PARTNERSHIP CONTACT: